About: Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on June 2009

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2009 (ast) наукова стаття, опублікована в червні 2009 (uk) مقالة علمية نشرت في يونيو 2009 (ar) scientific article published on June 2009 (en)
publication date	wds:Q37338133-2B00E7C3-1F74-484F-85C9-7E98742ACA44
publication date	2009-06-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37338133-7F137E7A-7DCB-486D-B6A5-966A2C447D66
language of work or name	English
cites work	wds:Q37338133-0CA8D788-9DE1-44FE-83CB-0382C0FD1DA0 wds:Q37338133-28FA734B-069A-4C3A-AFC3-965B79B434FD wds:Q37338133-3056C8AE-A25C-49A1-8794-6CC8EF650DD4 wds:Q37338133-34F909DC-12E7-429E-8E0F-8DEAC7EA5CA5 wds:Q37338133-378809AE-3FA5-44E3-A9EA-4D9D3DBB8653 wds:Q37338133-3EB42F72-0CE7-4F5F-A336-C9326AB394D0 wds:Q37338133-401D13B8-9388-46EF-B997-563A88F89C4F wds:Q37338133-42332F35-704F-475F-A4CE-0078CDCC0826 wds:Q37338133-49E40094-88BC-4889-95BE-1FB2C8F09E5C wds:Q37338133-50A47EA7-0B5D-4DDD-BDAD-99C0287390C2 wds:Q37338133-52859216-1533-4B65-A14C-769F0AFE4EE0 wds:Q37338133-5ECC8BBD-164C-4A6C-8690-5B87A27D3255 wds:Q37338133-612AE8D3-EED3-4EBE-80D0-AD0E1A42816E wds:Q37338133-7A4D8C4E-3935-41EE-9843-5A44A726E5E7 wds:Q37338133-84F72183-5D04-4ACD-B5DA-BDA44CC3C507 wds:Q37338133-9A7B7237-8BD9-4DBB-8295-FF3CE561B38F wds:Q37338133-A92306E7-CF54-46D3-B9D2-EB2AC24D28FA wds:Q37338133-AEECB4AD-0AE5-41E9-B35C-7F0AA9D0E288 wds:Q37338133-B5234EF6-DCA0-4AAB-B724-BEA1277CB2F8 wds:Q37338133-B9D767E1-9393-4B69-A947-33F3B34A5ECB wds:Q37338133-C02F3AF0-2F84-4F45-BBF6-D4783E3E6C27 wds:Q37338133-C2ED733D-C08B-48A9-9B91-79845EFDEC4B wds:Q37338133-CB549CDF-1532-4488-95B7-6DB748D0829C wds:Q37338133-D49E287D-6FDC-4E91-9524-DDD0568A23B1 wds:Q37338133-E7B9202E-CD12-428E-8812-ACE06D1E00E7 wds:Q37338133-EDE42BA7-F22F-4284-B885-AED1E8210AC7 wds:Q37338133-F2D93B81-D84D-4B44-895E-F12EC51697B8 wds:Q37338133-F38E0B62-EACE-4FD7-8915-6132A3A8D1C2 wds:Q37338133-F58C53B5-109D-4DEC-9A45-C5B93FE20059
cites work	Evaluation of methods for the measurement of low-density lipoprotein cholesterol. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population HIV lipodystrophy: prevalence, severity and correlates of risk in Australia Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial Cardiovascular risk and body-fat abnormalities in HIV-infected adults Combination antiretroviral therapy and the risk of myocardial infarction Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides Long-Term Body Fat Outcomes in Antiretroviral-Naive Participants Randomized to Nelfinavir or Efavirenz or Both Plus Dual Nucleosides Class of Antiretroviral Drugs and the Risk of Myocardial Infarction Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy Fat distribution in men with HIV infection Redefining lipodystrophy syndrome: risks and impact on clinical decision making An objective case definition of lipodystrophy in HIV-infected adults: a case-control study Class-sparing regimens for initial treatment of HIV-1 infection A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus G Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095) In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy
author name string	wds:Q37338133-13E39228-09C9-4FCF-A384-8E7D487B29C0 wds:Q37338133-18C9FE4E-A2EB-4A03-83FA-89583FDDF32D wds:Q37338133-1E6CCB81-AD1D-4D35-AB10-D5AFD6A97236 wds:Q37338133-2CF8A130-9690-45A9-B36D-796DB22064A5 wds:Q37338133-300A108F-C10F-488F-AFF7-489FD0646BB8 wds:Q37338133-4ADDB7C9-E6CA-4170-A4DA-373E650C938F wds:Q37338133-4F79682E-0C4B-468E-902D-2CAD45969CE3 wds:Q37338133-5BA0A99F-227C-4124-945A-B20C33E7D20F wds:Q37338133-77B0CBBC-5977-420A-8746-E29BD635D4C9 wds:Q37338133-B6C8B049-30BF-4C54-9EA2-C69D51ED0BC3 wds:Q37338133-DEA5FBC2-3F7F-441E-8B72-65331F60E915
author name string	John W Mellors Sharon A Riddler James F Rooney Lauren Komarow David W Haas Richard H Haubrich Karin Klingman A Gregory DiRienzo AIDS Clinical Trials Group (ACTG) A5142 Study Team David L Butcher

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software